# AgomAb Therapeutics NV (AGMB)

> Source: Nexqual · https://nexqual.com/AGMB · data as of 2026-11-18 21:00 UTC · cite as "Nexqual, AgomAb Therapeutics NV (AGMB), nexqual.com/AGMB" · informational, not investment advice.

## What changed for AGMB since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

- Analyst actions on AGMB in the last 120 days: 3 (0 upgrades or target raises, 0 downgrades or target cuts); most recent Piper Sandler, Aug 25, 2026.

**Price:** USD 5.82 (-1.69% on the day) · last close of Nov 18, 2026; US market after hours, not a live price. Prev close 5.92 · day 5.7–6.25 · 52w 5.5–17.82 · market cap $287M · NMS

## Key facts
- Insider open-market purchases, last ~7 months: 7 Form 4 filings, $592K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.57 on a 1–5 scale) (7 analysts), mean target USD 37.67 (range 28–60).
- Total return with dividends: 1Y -60.8% vs S&P 500 +11.4%; 5Y -60.8% vs S&P 500 +66.5%.
- Dividend: AGMB paid no cash dividend in the last five years.
- Short interest: 2.26% of float (as of 2026-10-30), 6.1 days to cover.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
7 purchases, $592K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-11-13 | Epstein David R | Director | 14,980 | $89K | 5.92 | Too little history (no open-market trades in 2023–2025) |
| 2026-11-05 | Epstein David R | Director | 15,000 | $104K | 6.9 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-21 | Epstein David R | Director | 10,000 | $89K | 8.88 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-08 | Epstein David R | Director | 5,000 | $45K | 8.9 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05…2026-10-06 | Epstein David R | Director | 10,000 | $86K | 8.63 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-06 | Kemula Pierre Thadee Victor | Chief Financial Officer | 10,000 | $86K | 8.59 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05…2026-10-06 | Knotnerus Tim Jasper | Chief Executive Officer | 11,000 | $94K | 8.58 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.57 on a 1–5 scale), 7 analysts; mean target USD 37.67 (low 28, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-25 | Piper Sandler | Initiated | Overweight | $60 |
| 2026-08-19 | Cantor Fitzgerald | Initiated | Overweight |  |
| 2026-07-23 | B. Riley Securities | Initiated | Buy | $34 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-02-06) | 5Y (from 2026-02-02) |
|---|---|---|
| Total return | -60.8% | -60.8% |
| S&P 500 (SPY) | +11.4% | +66.5% |
| Per year | — | — |
| Volatility (annualized) | 91.9% | 74.7% |
| Max drawdown | -67.8% (Jun 2026→Nov 2026) | -64.2% (Feb 2026→Nov 2026) |

## Dividends
AGMB paid no cash dividend in the last five years.

## Short interest
920,851 shares sold short, 2.26% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,001,145 shares (-8.0%). Days to cover: 6.1 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 97.81 +1.04% · BLTE (Belite Bio, Inc) USD 156.23 -0.94% · ORKA (Oruka Therapeutics, Inc.) USD 95.74 -0.60% · IBRX (ImmunityBio, Inc.) USD 6.7 +7.03% · IMVT (Immunovant, Inc.) USD 33.17 -0.12% · CGON (CG Oncology, Inc.) USD 80 +1.34%

## More
Full page: https://nexqual.com/AGMB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.36 | $-0.48 | +$0.12 | $0 | 3 |
| Next quarter (ends 2026-12-31) | $-0.42 | $-0.54 | +$0.13 | $0 | 3 |
| Current fiscal year (ends 2026-12-31) | $-1.81 | $-1.85 | +$0.05 | $0 | 6 |
| Next fiscal year (ends 2027-12-31) | $-2.02 | $-2.08 | +$0.06 | $0 | 6 |

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | Schedule 13G/A | Redmile Group, LLC, Jeremy C. Green: 3.5% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/2020932/000090514826004929/0000905148-26-004929-index.htm |
| 2026-10-13 | 6-K | Current report (foreign issuer) · period ended Oct 13, 2026 | https://www.sec.gov/Archives/edgar/data/2020932/000110465926115567/0001104659-26-115567-index.htm |
| 2026-10-01 | 6-K | Current report (foreign issuer) · period ended Oct 1, 2026 | https://www.sec.gov/Archives/edgar/data/2020932/000110465926112564/0001104659-26-112564-index.htm |
| 2026-09-14 | 6-K | Current report (foreign issuer) · period ended Sep 14, 2026 | https://www.sec.gov/Archives/edgar/data/2020932/000110465926107500/0001104659-26-107500-index.htm |
| 2026-09-11 | 6-K | Current report (foreign issuer) · period ended Sep 11, 2026 | https://www.sec.gov/Archives/edgar/data/2020932/000110465926107117/0001104659-26-107117-index.htm |
| 2026-08-10 | 6-K | Current report (foreign issuer) · period ended Aug 10, 2026 | https://www.sec.gov/Archives/edgar/data/2020932/000110465926093390/0001104659-26-093390-index.htm |
| 2026-08-06 | 6-K | Current report (foreign issuer) · period ended Aug 6, 2026 | https://www.sec.gov/Archives/edgar/data/2020932/000110465926091992/0001104659-26-091992-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
